An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|ClinicalTrials.gov Identifier: NCT01062451|
Recruitment Status : Active, not recruiting
First Posted : February 4, 2010
Last Update Posted : July 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Methamphetamine Dependence Methamphetamine Abuse Substance Abuse||Drug: Perindopril Drug: Placebo Drug: Candesartan||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence|
|Study Start Date :||May 2009|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
|Placebo Comparator: Placebo||
Placebo treatment daily.
Other Name: Sugar pill
|Active Comparator: Perindopril||
8 mg taken orally from days 0 through 7.
Other Name: Aceon
|Active Comparator: Candesartan||
16 mg taken orally from days 0 through 7.
Other Name: Atacand
- The dose-dependent effects of an ace inhibitor or an angiotensin receptor blocker on MA- and cue-induced craving and on the reinforcing effects of MA indexed by MA self-administration. [ Time Frame: 7 days ]Participants demonstrating MA-induced craving will then be randomized to active study medication (perindopril or candesartan) or matched placebo (day 0). Over days 4 to 7 a variety of procedures will be completed to assess effects of MA and cue-induced craving. On day 7, reinforcing effects will be assessed will be assessed using self-administration procedures.
- The effects of an ace inhibitor or an angiotensin receptor blocker on subjective measures. [ Time Frame: 7 days ]On days 3 and 5, participants will receive sample doses of 15mg or 30mg MA paired with a dose of placebo saline separated by 180 min, with the order of administration randomized. Subjective effects of MA will be assessed using visual analogue scales (VAS).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01062451
|United States, Texas|
|Michael E. DeBakey VA Medical Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Thomas F Newton, M.D.||Baylor College of Medicine|